Table 4.
No. of Reported Industry Payments | Injections by Category, Median, % | P Value | |
---|---|---|---|
Aflibercept and Ranibizumab | Bevacizumab | ||
0 (n = 1867) | 16.5 | 83.5 | <.001 |
1 (n = 434) | 37.0 | 63.0 | <.001 |
2 (n = 274) | 53.9 | 46.1 | .81 |
3–5 (n = 278) | 64.4 | 35.6 | <.001 |
>5 (n = 158) | 78.1 | 21.9 | <.001 |